Core Viewpoint - The company has announced the return of funds used for temporarily supplementing working capital, ensuring compliance with regulations and proper disclosure [1][3]. Group 1 - The company held its fifth board meeting and supervisory board meeting on August 15, 2024, where it approved the use of up to 494.80 million yuan of idle raised funds to temporarily supplement working capital [2]. - The approved amount includes a maximum of 396.00 million yuan from convertible bond idle funds and 98.80 million yuan from non-publicly issued stock idle funds, with a usage period of twelve months from the board's approval date [2]. - As of the announcement date, the company has returned all funds used for temporarily supplementing working capital to the corresponding special account, and the usage period did not exceed twelve months [3].

Group 1 - The company held its 19th meeting of the third supervisory board on August 13, 2025, with all three supervisors present, and the meeting was deemed legal and effective [3] - The supervisory board approved the company's 2025 semi-annual report and its summary, confirming that the report's preparation and review processes complied with relevant laws and regulations [4] - The supervisory board also approved the special report on the storage and actual use of raised funds for the first half of 2025, stating that the management of raised funds adhered to regulatory requirements [6] Group 2 - The company plans to change its auditing firm to Ernst & Young Huaming, as the previous firm, Lixin, has provided services for ten consecutive years [24][32] - The decision to change the auditing firm was based on the need for new auditing services aligned with the company's business development and future audit requirements [32] - The company has communicated with both the outgoing and incoming auditing firms regarding this change, and both parties have no objections [32] Group 3 - The company reported that as of June 30, 2025, it had raised a total of RMB 555.86 million from its initial public offering, with a net amount of RMB 496.47 million after deducting related expenses [12][13] - By June 30, 2025, the company had used RMB 515.85 million of the raised funds for projects and incurred RMB 59.39 million in issuance costs, with a remaining balance of RMB 3.06 million in the raised funds account [13] - The company has implemented strict management of raised funds, ensuring they are stored in dedicated accounts and used for their intended purposes [14] Group 4 - The company has proposed changes to its registered capital and amendments to its articles of association, which were approved during the board meeting on August 13, 2025 [38][39] - The registered capital increased from RMB 630.58 million to RMB 634.80 million following the completion of the stock incentive plan [38] - The amendments to the articles of association will be finalized based on the approval from the relevant registration authority [39] Group 5 - The company announced the convening of its second extraordinary general meeting of 2025, scheduled for September 1, 2025, to discuss various proposals [41][42] - The meeting will utilize a combination of on-site and online voting methods, allowing shareholders to participate remotely [43] - Shareholders must register for the meeting by August 29, 2025, and can delegate representatives to attend [55]

Group 1 - The company has successfully raised a total of RMB 1,170,000,000 through the issuance of convertible bonds, with a net amount of RMB 1,158,921,603.78 after deducting issuance costs [2][3] - The funds have been deposited as of August 12, 2025, and the verification report has been issued by Zhongxinghua Accounting Firm [2][3] - A special account for the management of the raised funds has been established, and a tripartite supervision agreement has been signed to ensure proper usage and storage of the funds [3][4] Group 2 - The tripartite agreement involves the company, the banks where the funds are stored, and the sponsor, CITIC Securities, to regulate the management of the raised funds [4][7] - The special account is exclusively for the company's semiconductor thin film deposition equipment project, and funds cannot be used for other purposes [7][12] - The company is required to notify the sponsor of any cash management products and ensure that these products are not pledged [8][12] Group 3 - The sponsor has the right to conduct ongoing supervision of the fund management and can perform on-site investigations [8][19] - Monthly account statements must be provided by the banks to both the company and the sponsor [20][21] - Any significant withdrawals exceeding 20% of the net raised funds must be reported to the sponsor within two working days [20][21]

Group 1 - The company held its sixth board meeting on August 14, 2025, with all seven directors present, and the meeting complied with relevant regulations [5][6]. - The board approved the 2025 semi-annual report and summary, confirming that the report accurately reflects the company's financial status and operational results [6][8]. - The board also approved the special report on the storage and use of raised funds, affirming compliance with regulations and proper management of the funds [9][10]. Group 2 - The company raised a total of RMB 805,890,800.00 from its initial public offering, with a net amount of RMB 725,866,140.61 after deducting issuance costs [13][14]. - As of June 30, 2025, the company had utilized RMB 562,780,017.53 of the raised funds, leaving a balance of RMB 187,562,491.34 [15]. - The company has implemented a cash management plan for temporarily idle raised funds, with a balance of RMB 156,900,000.00 as of June 30, 2025 [21][22]. Group 3 - The supervisory board confirmed that the procedures for compiling and reviewing the semi-annual report were in accordance with legal requirements, ensuring the report's accuracy and completeness [27][28]. - The supervisory board also approved the special report on the storage and use of raised funds, affirming that the company adhered to regulations and did not misuse the funds [29][30]. - The supervisory board evaluated the semi-annual assessment report on the quality improvement and efficiency enhancement action plan, confirming its alignment with the company's strategic goals [31][32].

Group 1 - The core viewpoint of the report is to provide a detailed account of the fundraising activities and the management of raised funds by Chengdu Saintno Biological Technology Co., Ltd. for the first half of 2025 [4][6][26] - The company successfully raised a total of RMB 358 million through the issuance of 20 million shares at a price of RMB 17.90 per share, with a net amount of RMB 285.2 million after deducting issuance costs [4][6] - As of June 30, 2025, the company has utilized RMB 12.57 million of the raised funds for investment projects, with a cumulative usage of RMB 295.9 million [6][8] Group 2 - The company has established a management system for the raised funds, ensuring they are stored in dedicated accounts and used according to regulatory requirements [7][25] - There were no instances of changing the use of raised funds or using idle funds for temporary liquidity needs during the reporting period [10][13] - The company has a plan to use up to RMB 70 million of temporarily idle self-owned funds for entrusted financial management, aiming to enhance the efficiency of fund usage without affecting daily operations [20][26]

Core Viewpoint - The company has released its 2025 semi-annual report, ensuring the accuracy and completeness of the information provided, and has outlined its financial performance and future plans [1][4][5]. Group 1: Company Overview - The company is known as Tianjin Yao Daren Tang Group Co., Ltd., with the stock code 600329 [4]. - The report is unaudited and emphasizes the importance of reviewing the full semi-annual report for a comprehensive understanding of the company's performance [2][1]. Group 2: Financial Data - The company raised a total of RMB 836.08 million through a non-public offering of shares, with a net amount of RMB 814.34 million after deducting fees [24]. - As of June 30, 2025, the company has utilized RMB 669.88 million for investment projects and has a remaining balance of RMB 57.21 million in its fundraising account [24]. Group 3: Important Resolutions - The board approved the semi-annual report and a special report on the use of raised funds, with unanimous support from all attending directors [7][17]. - A proposal to purchase liability insurance for the company's directors, supervisors, and senior management was also approved, with an insurance limit of up to RMB 100 million [46]. Group 4: Fund Management - The company has established a management method for raised funds to ensure compliance with legal regulations and to protect investor rights [25]. - The company has permanently supplemented its working capital with RMB 150.14 million from surplus raised funds as of June 30, 2025 [37]. Group 5: Compliance and Reporting - The company has adhered to the regulations set by the China Securities Regulatory Commission and the Shanghai Stock Exchange regarding the management and disclosure of raised funds [43].

Core Viewpoint - The company is advancing its strategic development by investing in a new manufacturing facility and adjusting its fundraising projects to meet market demands, with a focus on enhancing production capacity for key pharmaceutical products. Group 1: Company Overview - The company has signed an investment cooperation agreement with the Dongyang Economic Development Zone Management Committee to invest in the "Haisen Pharmaceutical New Plant Construction Project (Phase I)" with a total investment of no less than 2 billion RMB [5]. - The company has not changed its controlling shareholder or actual controller during the reporting period [4][5]. Group 2: Financial Data and Fundraising - The company raised a total of 756.16 million RMB from its initial public offering, with a net amount of 675.72 million RMB after deducting underwriting fees and other expenses [10]. - As of June 30, 2025, the company had a balance of 7.53 million RMB in unused raised funds, with 4 million RMB allocated for permanent working capital and 3.53 million RMB for the new project [21]. Group 3: Project Updates - The company has changed its fundraising project from "Annual Production of 200 Tons of Atorvastatin Calcium Technical Transformation Project" to "Annual Production of 300 Tons of A-40 (Atorvastatin Calcium) and Other Specialty Raw Material Construction Project" to better align with market trends [6]. - The construction of the R&D center and comprehensive office building has been completed, with equipment installation ongoing, leading to a delay in the investment schedule [7]. Group 4: Profit Distribution and Capital Changes - The company approved a profit distribution plan for 2024, which includes a cash dividend of 1.70 RMB per 10 shares and a capital reserve transfer of 4.8 shares for every 10 shares held [8]. - The registered capital has increased from 102.65 million RMB to 151.93 million RMB following the implementation of the profit distribution plan [8]. Group 5: Regulatory Compliance - The company has adhered to regulations regarding the management and use of raised funds, ensuring that there are no violations in the storage, usage, and disclosure of these funds [25].

Summary of Key Points Core Viewpoint The report provides a detailed account of Dongguan Darui Electronics Co., Ltd.'s fundraising activities, including the total amount raised, the usage of funds, and the management of these funds as of June 30, 2025. It highlights the company's compliance with regulatory requirements and outlines the financial status of its fundraising projects. Fundraising Overview - The company raised a total of RMB 2,193,016,056.00 through its initial public offering, with a net amount of RMB 2,038,096,865.89 after deducting issuance costs [1] - The funds were fully received by April 12, 2021, and verified by an accounting firm [1] Fund Usage and Balance - As of June 30, 2025, the net amount of raised funds was RMB 203,809.69 million, with cumulative investments in fundraising projects totaling RMB 143,402.16 million [2] - The company invested RMB 16,792.00 million in fundraising projects during the reporting period [2] - The remaining balance of unused funds was RMB 63,419.17 million, including RMB 58,400.00 million temporarily idle for cash management [2] Fund Management - The company established a fundraising management system in compliance with relevant regulations, including a dedicated management method for the storage and use of funds [2] - Special accounts were opened for the management of fundraising funds, and a tripartite supervision agreement was signed with several banks [2][3] Cash Management - The company has been authorized to use up to RMB 11 billion of temporarily idle funds for cash management, with a subsequent approval to use up to RMB 8 billion [6] - As of June 30, 2025, the company earned RMB 518.92 million from cash management activities [8] Project Implementation and Adjustments - The "3C Electronic Assembly Automation Equipment Production Project" and "Wearable Electronic Product Structural Parts Production Project" have reached their intended usable status as of March 25, 2024, and March 25, 2025, respectively [9][10] - The company has not made any changes to the implementation locations or methods of fundraising projects as of June 30, 2025 [12] Surplus Fund Usage - Surplus funds from the projects have been permanently allocated to supplement working capital, with specific amounts detailed for each project [9][10][14] - The company has also reported on the usage of over-raised funds, with a total of RMB 56,869.28 million in surplus funds, of which RMB 1,322.72 million remains unallocated [14]

招商证券股份有限公司 关于盛视科技股份有限公司 经中国证券监督管理委员会《关于核准盛视科技股份有限公司首次公开发行 股票的批复》（证监许可[2020]663 号）文件核准，公司首次公开发行人民币普 通股（A 股）股票 3,156 万股，发行价格为人民币 36.81 元/股（不含送转），本 次募集资金总额为人民币 1,161,723,600.00 元，扣除发行费用（不含增值税）人 民币 124,963,600.00 元后，实际募集资金净额为人民币 1,036,760,000.00 元。上 述募集资金到账后，天健会计师事务所（特殊普通合伙）于 2020 年 5 月 20 日对 公司首次公开发行股票的募集资金到位情况进行了审验，并出具了《验资报告》 （天健验[2020]7-37 号）。公司与募集资金开户银行、保荐机构签署《募集资金 三方监管协议》，开立了募集资金专项账户。三方监管协议与深圳证券交易所三 方监管协议范本不存在重大差异，公司在使用募集资金时已经严格遵照履行。 （二）募投项目情况 公司首次公开发行股票募投项目及募集资金使用计划如下： 承诺使用募集 投资总额 项目达到预定 可使 序号 项目 资金金额 （万元 ...

Core Points - The report details the fundraising and usage status of Jinan Mankun Technology Co., Ltd. for the first half of 2025, ensuring compliance with relevant regulations and accurate disclosure [1][4][8] Fundraising Overview - The company raised a total of RMB 988.12 million through its initial public offering, with a net amount of RMB 874.44 million after deducting issuance costs [1] - The funds were deposited into a dedicated account on August 5, 2022, and verified by Tianjian Accounting Firm [1] Fund Usage and Management - As of June 30, 2025, the company had utilized RMB 129.92 million of the raised funds, with a remaining balance of RMB 398.98 million in the dedicated account [2][4][7] - The company has established a fundraising management system and signed a tripartite supervision agreement with Agricultural Bank of China and its sponsor, Zhongtai Securities [2][4] Financial Details - The company reported a net interest income of RMB 12.74 million as of the beginning of the period, with a total of RMB 25.42 million in interest income by the end of the period [2][4] - The total amount of funds invested in projects reached RMB 500.89 million, representing 57.28% of the total committed investment [8] Project Implementation - The company has not changed the implementation location or method of its fundraising projects during the reporting period [4] - The company approved the use of RMB 50.64 million of raised funds to replace pre-invested self-raised funds and issuance costs [4][5] Idle Fund Management - The company has not used idle funds to supplement working capital as of June 30, 2025, and has plans to manage idle funds through safe and liquid investment products [5][7] - The maximum amount of idle funds used for cash management in the reporting period was RMB 550 million [7] Compliance and Reporting - The company confirmed that there were no issues with the disclosure of fundraising usage, and all information was timely and accurate [8] - There were no changes in the fundraising project or any violations in the management and disclosure of the funds [8]